D. Blom

发表

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

J. Gibbs, M. Emery, M. Gibbs, 2016, Journal of clinical pharmacology.

CEPHEUS SA: a South African survey on the under-treatment of hypercholesterolaemia

F. Raal, G. Vandenhoven, Fatima Cassim, 2011, Cardiovascular journal of Africa.

Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus.

N. Sattar, H. Soran, M. Cyrille, 2017, The American journal of cardiology.

Lipids are vital to life, but are important contributors to pathology.

D. Blom, 2009 .

Proprotein convertase subtilisin/kexin type 9 inhibition

G. Lambert, Y. Gouëffic, D. Marais, 2012, Current opinion in lipidology.

Effects of Evolocumab on Vitamin E and Steroid Hormone LevelsNovelty and Significance

D. Blom, S. Wasserman, R. Scott, 2015 .

Effect of hyperthermia on expression of histocompatibility antigens and heat-shock protein molecules on three human ocular melanoma cell lines.

G. Luyten, M. Jager, R. Apte, 1997, Melanoma research.

Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief Report

K. Hovingh, F. Raal, G. Dallinga-Thie, 2016, Arteriosclerosis, thrombosis, and vascular biology.

Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma.

A. Zwinderman, G. Luyten, M. Jager, 1997, Investigative ophthalmology & visual science.

Elevated triglycerides: A matter of the heart and pancreas

D. Blom, 2018 .

INVERSE CORRELATION BETWEEN EXPRESSION OF HLA‐B AND c‐myc IN UVEAL MELANOMA

A. Zwinderman, I. Ouwerkerk, P. Schrier, 1997, The Journal of pathology.

New therapeutic developments in lipidology Since the previous CME on lipidology

D. Blom, 2009 .

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

C. Ballantyne, E. Stein, R. Češka, 2014, The New England journal of medicine.

Evolocumab in hyperlipidemia.

E. Stein, S. Wasserman, D. Blom, 2014, The New England journal of medicine.

Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia

S. Young, C. Pullinger, D. Blom, 2017, The New England journal of medicine.

Acute Pancreatitis is Highly Prevalent and Complications can be Fatal in Patients with Familial Chylomicronemia: Results From a Survey of Lipidologist

D. Gaudet, M. Malloy, E. Bruckert, 2016 .

Effects of transpupillary thermotherapy on immunological parameters and apoptosis in a case of primary uveal melanoma.

M. Jager, J. Prause, L. R. Schurmans, 1999, Melanoma research.

The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS).

D. Gaudet, Joann D Flaim, L. Hemphill, 2017, Atherosclerosis.

Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa

L. Morris, M. Mendelson, G. Maartens, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.

F. Claas, M. Jager, A. Gorter, 1996, Investigative ophthalmology & visual science.

Multidrug resistance-related proteins in primary choroidal melanomas and in vitro cell lines.

M. Flens, G. Luyten, M. Jager, 1997, Investigative ophthalmology & visual science.

HLA expression in a primary uveal melanoma, its cell line, and four of its metastases

M. Jager, D. de Wolff-Rouendaal, L. R. Schurmans, 1997, The British journal of ophthalmology.

Decreased expression of HLA class I on ocular melanoma cells following in vitro photodynamic therapy.

T. Dubbelman, M. Jager, H. Schuitmaker, 1997, Cancer letters.

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.

N. Paynter, P. Ridker, J. Buring, 2022, The New England journal of medicine.

Statin therapy for the octogenarian?

D. Blom, D. Blom, 2012 .

Effect of Evolocumab on Lipoprotein Particles.

S. Martin, Steven R. Jones, N. Sattar, 2018, The American journal of cardiology.

Abstract 16865: Safety and Tolerability of Very Low LDL-C Levels in Patients Treated with 52 Weeks of Evolocumab (AMG 145)

R. Giugliano, E. Stroes, S. Wasserman, 2014 .

Dyslipidaemia in Type 2 diabetes : review

D. Blom, 2013 .

Lack of effect of different cytokines on expression of membrane-bound regulators of complement activity on human uveal melanoma cells.

F. Claas, G. Luyten, M. Jager, 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

New therapeutic developments in lipidology

A. Marais, D. Blom, 2009 .

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

C. Ballantyne, E. Stein, R. Češka, 2014, The New England journal of medicine.

HLA expression in a primary uveal melanoma, its cell line, and four of its metastases

M. Jager, D. Blom, J. Keunen, 1997, The British journal of ophthalmology.

Multidrug resistance: related proteins in primary chorpoidal melanoma and in vitro cell lines

M. Flens, D. Blom, Leo Koornneef, 1997 .

Autoantibodies against GPIHBP 1 as a Cause of Hypertriglyceridemia

S. Young, Minrong Ai, C. Pullinger, 2017 .

Familial Chylomicronemia Syndrome (FCS) Patients Recruited to the APPROACH Trial of Volanesorsen Therapy are Representative of Subjects with FCS

D. Gaudet, M. Malloy, J. Kane, 2017 .

Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa

Raubenheimer, L. Morris, G. Maartens, 2021 .